The DIVERSE Trials Act (H.R. 5030/S. 2706) could increase racial, socioeconomic and geographic diversity in clinical trials and make it easier for all cancer patients to participate.
Joint Letter in Support of NAIC Consumer Representatives' Comments on Formulary Model Act
In a letter to the National Association of Insurance Commissioners (NAIC), ACS CAN and other organziations provided specific comments to provide greater consumer protections and improvements to the NAIC's Health Carrier Prescription Drug Benefit Model Act (Formulary Model Act).